pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma

Sorafenib is a multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma (HCC). However, therapeutic response to sorafenib was not equal among HCC patients. Here we present a novel system to provide quantitative information concerning sorafenib-related targets by simultan...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jun, Shi, Lehua, Zhang, Xiaofeng, Sun, Bin, Yang, Yefa, Ge, Naijian, Liu, Huiying, Yang, Xia, Chen, Lei, Qian, Haihua, Wu, Mengchao, Yin, Zhengfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823061/
https://www.ncbi.nlm.nih.gov/pubmed/26544731
http://dx.doi.org/10.18632/oncotarget.6104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823061/
https://www.ncbi.nlm.nih.gov/pubmed/26544731
http://dx.doi.org/10.18632/oncotarget.6104

Ejemplares similares